The company is focused on holistic medicine, nutritional supplements and “nutraceuticals” and aims to buy and scale around 15 brands over the next three years.
“The problem is every celebrity you can name is creating their own nutraceuticals and there is no credibility anymore for that, so there needs to be some kind of scientific validation,” Mr. Chopra told CNBC. “I decided I could help them with scientific validation of products and services.”
The company should also look into the use of psychedelics such as psilocybin and ketamine for treating mental health disorders, Mr. Chopra told CNBC.
Other investors include Dragons’ Den’s Steven Bartlett and psychedelics entrepreneur Christian Angermayer, who bought a stake in the company during a $10 million seed round.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
